Market Currents
Watson Pharmaceuticals (WPI +2.8%) gains on an upgrade to Outperform on valuation at Wells...
-
Thursday, May 24, 2012, 10:30 AM ETWatson Pharmaceuticals (WPI +2.8%) gains on an upgrade to Outperform on valuation at Wells Fargo. Wells says that on deeper analysis, it has higher confidence in the company's ability to hit EPS targets following the Actavis acquisition. The firm also raises its price target range to $84 - $90 from $75 - $79.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
